Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-proliferative Diabetic Retinopathy (NPDR)
Open-angle Glaucoma (OAG)
Normal Tension Glaucoma (NTG)

Interventions

DRUG: QLS-111 Ophthalmic Solution (0.015%)
DRUG: QLS-111 Ophthalmic Solution (0.075%)

Sponsor

Qlaris Bio, Inc.